Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures.

ABSTRACT:

Background

Achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI90) is achievable with newer biologic therapies, such as ixekizumab. Standard of care payment systems such as the Merit-based Incentive Payment System (MIPS) responder criteria could lead to under treatment and lower quality of life (QoL) outcomes compared with PASI90.

Objective

Show PASI90 is a higher standard than MIPS and is associated with greater improvements in QoL and other PRO outcomes.

Methods

Patients with moderate-to-severe psoriasis meeting PASI90 and MIPS criteria were compared in 3 phase 3 clinical trials of the interleukin-17A inhibitor ixekizumab (pooled UNCOVER-2/3 and IXORA-S). Patients satisfying MIPS criteria met either static Physician Global Assessment score ≤2, body

SUBMITTER: Hawkes JE 

PROVIDER: S-EPMC11361529 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature